Cardiac: Is this biomarker ready for the prime time?

References

• Panteghini M. The basics of cardiac marker interpretation. Biochim Clin 2007;31:9–12.
   Google Scholar
• Thygesen K, Alpert JS, White HD on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007;116:2634–53.
   PubMed Web of Science ®Google Scholar
• Sanchis J, Bodí V, Llácer A, Núñez J, Consuegra L, Bosch MJ, Bertomeu V, Ruiz V, Chorro FJ. Risk stratification of patients with acute chest pain and normal troponin concentrations. Heart 2005;91:1013–8.
   PubMedGoogle Scholar
• Panteghini M. Acute coronary syndrome biomarkers. RIMeL/IJLaM 2005;1:30–6.
   Google Scholar
• Heeschen C, Dimmeler S, Hamm CW, van der Brand MJ, Boersma E, Zeiher AM, Simoons ML. Soluble CD40 ligand in acute coronary syndrome. N Engl J Med 2003;348: 1104–11.
   PubMed Web of Science ®Google Scholar
• Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schönbeck U. Soluble CD40L. Risk prediction after acute coronary syndromes. Circulation 2003;108:1049–52.
   PubMed Web of Science ®Google Scholar
• Halldórsdóttir AM, Stoker J, Porche-Sorbet R, Eby CS. Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method. Clin Chem 2005;51:1054–7.
   PubMed Web of Science ®Google Scholar
• Ivandic BT, Spanuth E, Haase D, Lestin HG, Katus HA. Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem 2007;53:1231–4.
   PubMed Web of Science ®Google Scholar
• Panteghini M. The importance of analytical quality specifications for biomarker assays currently used in acute cardiac care. Acute Card Care 2006;8:133–8.
   PubMedGoogle Scholar
• Panteghini M, Gerhardt W, Apple FS, Dati F, Ravkilde J, Wu AH. Quality specifications for cardiac troponin assays. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Clin Chem Lab Med 2001;39: 174–8.
   Google Scholar
• Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AHB, Tate J, . Quality specification for B-type natriuretic peptide assays. Clin Chem 2005;51:486–93.
   PubMed Web of Science ®Google Scholar
• Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J, . Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51:810–24.
   PubMed Web of Science ®Google Scholar
• Vasan RS. Biomarkers of cardiovascular disease. Molecular basis and practical considerations. Circulation 2006;113: 2335–62.
   PubMed Web of Science ®Google Scholar
• Jaffe AS, Katus H. Acute coronary syndrome biomarkers. The need for more adequate reporting. Circulation 2004; 110:104–6.
   PubMed Web of Science ®Google Scholar
• Mair J. Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage. Clin Chim Acta 1998;272: 79–86.
   PubMed Web of Science ®Google Scholar
• Zarich S, Bradley K, Seymour J, Ghali W, Traboulsi A, Mayall ID, Bernstein L. Impact of troponin T determinations on hospital resource utilization and costs in the evaluation of patients with suspected myocardial ischemia. Am J Cardiol 2001;88:732–6.
   PubMedGoogle Scholar
• Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007;27:15–26.
   PubMed Web of Science ®Google Scholar
• Jesse RL. Rationale for the early clinical application of markers of ischemia in patients with suspected acute coronary syndromes.Cardiac Markers, 2nd. Wu AHB. Humana Press, Totowa, NJ, 2003:245–57.
   Google Scholar
• Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-A preliminary report. J Emerg Med 2000;19:311–5.
   PubMed Web of Science ®Google Scholar
• Gidenne S, Ceppa F, Fontan E, Perrier F, Burnat P. Analytical performance of the albumin cobalt binding (ACB®) test on the Cobas MIRA® Plus analyzer. Clin Chem Lab Med 2004;42:455–61.
   PubMed Web of Science ®Google Scholar
• Maguire OC, O'Sullivan J, Ryan J, Cunningham SK. Evaluation of the albumin cobalt binding (ACB®) assay for measurement of ischaemia-modified albumin (IMA®) on the Beckman Coulter LX-20. Ann Clin Biochem 2006;43: 494–9.
   PubMedGoogle Scholar
• Seamonds B. The effect of sample storage conditions and time to assay performance on the measurement of ischemia modified albumin. Clin Chem 2009;55(suppl):A54.
   Google Scholar
• Gaze DC. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet 2009;24:333–41.
   PubMed Web of Science ®Google Scholar
• Roy D, Quiles J, Gaze DC, Collinson P Kaski JC, Baxter GF. Role of reactive oxygen species on the formation ofr the novel diagnostic marker ischaemia modified albumin. Heart 2006;92:113–4.
   PubMed Web of Science ®Google Scholar
• Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003; 107:2403–5.
   PubMed Web of Science ®Google Scholar
• Demir H, Topkaya BC, Erbay AR, Dogan vM, Yucel D. Ischaemia-modified albumin elevation after percutaneous coronary intervention reflects albumin concentration rather than ischaemia. Ann Clin Biochem 2009;46:327–31.
   PubMedGoogle Scholar
• Van der Zee PM, Verberne HJ, van Straalen JP, Sanders GTB, Van Eck-Smit BLF, de Winter RJ, Fischer JC. Ischemia-modified albumin measurements in symptom-limited exercise myocardial perfusion scintigraphy reflect serum albumin concentrations but not myocardial ischemia. Clin Chem 2005;51:1744–6.
   PubMed Web of Science ®Google Scholar
• Sbarouni E, Georgiadou P, Theodorakis GN, Kremastinos DT. Ischemia-modified albumin in relation to exercise stress testing. J Am Coll Cardiol 2006;48:2482–4.
   PubMed Web of Science ®Google Scholar
• Kurz K, Voelker R, Zdunek D, Wergeland R, Hess G, Ivendic B, Katus H, Giannitsis E. Effect of stress-induced reversible ischemia on serum concentrations of ischemia-modified albumin, natriuretic peptides and placental growth factor. Clin Res Cardiol 2007;96:152–9.
   PubMed Web of Science ®Google Scholar
• Anbwaruddin S, Jannuzzi Jr JL, Baggish AL, Lewandrowski EL, Lewandrowski KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 2005;123:140–5.
   PubMedGoogle Scholar
• Roy D, Quiles J, Aldama G, Sinha M, Avanzas P, Arroyo-Espliguero R, Gaze D, Collinson P, Kaski JC. Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol 2004;97:297–301.
   PubMed Web of Science ®Google Scholar
• Keating L, Benger JR, Beetham R, Bateman S, Veysey S, Kendall J, Pullinger R. The PRIMA Study: presentation ischaemia-modified albumin in the emergency department. Emerg Med J 2006;23:764–8.
   PubMedGoogle Scholar
• Talwalkar SS, Bon-Homme M, Miller JJ, Elin RJ. Ischemia modified albumin, a marker of acute ischemic events: a pilot study. Ann Clin Lab Sci 2008;38:132–7.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005;25:1102–11.
   PubMed Web of Science ®Google Scholar
• Tavora FR, Ripple M, Li L, Burke AP. Monocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques. BMC Cardiovasc Disord 2009;9:27.
   PubMed Web of Science ®Google Scholar
• Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595–604.
   PubMed Web of Science ®Google Scholar
• Esporcatte R, Cramer Veiga Rey H, Dias Rangel FO, Mourilhe Rocha R, de Mendonça Filho HTF, Rocha Dohmann HF, Albanesi Filho FM. Predictive value of myeloperoxidase to identify high risk patients admitted to the hospital with acute chest pain. Arq Bras Cardiol 2007;89:341–7.
   Google Scholar
• Eggers KM, Dellborg M, Johnston N, Oldgren J, Swahn E, Venge P, Lindahl B. Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clin Biochem 2010;43:240–5.
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Schnabel R, Lowenstein CJ, Caidahl K, Muenzel TF, Lubos E, Lackner KJ, Hollander JE. Diagnostic value of multimarker testing including myeloperoxidase in patients with acute coronary syndrome. Results from a Multicentre Biomarker Study. Circulation. 2006;114 (Suppl II):II–418.
   Google Scholar
• Scheffer PG, van der Zwan LP, Schindhelm RK, Vermue HPA, Teerlink T. Myeloperoxidase concentrations in EDTA-plasma of healthy subjects are discordant with concentrations in heparin-plasma and serum. Clin Biochem 2009;42:1490–2.
   PubMedGoogle Scholar
• Datwyler SA, Hsu SC, Matias MS, Pacenti DP, Shih J. Potential interference by antineutrophil cytoplasmic autoantibodies in myeloperoxidase immunoassays. Clin Chem 2008; 54:2084–6.
   PubMedGoogle Scholar